Lectin-like Ox-LDL Receptor Is Expressed in Human INT-407 Intestinal Cells: Involvement in the Transcytosis of Pancreatic Bile Salt–dependent Lipase

Nadine Bruneau,* Stéphane Richard, Françoise Silvy, Alain Verine, and Dominique Lombardo

INSERM U-559, Unité de Recherche de Physiopathologie des Cellules Epithéliales et Équipe d’Accueil 3289, Université de la Méditerranée, Faculté de Médecine, Marseilles, France

Submitted August 29, 2002; Revised March 13, 2003; Accepted March 2003

Monitoring Editor: Keith Mostov

We have recently shown that the pancreatic bile salt–dependent lipase (BSDL) can be taken up by intestinal cells and transported to the blood circulation. This mechanism likely involves (specific) receptor(s) able to bind BSDL and located at the apical intestinal cell membrane. In this study, using Int407 human intestinal cells cultured to form a tight epithelium, we attempted to characterize (the) BSDL receptor(s). We found that an apical 50-kDa protein was able to bind BSDL. Further, we have demonstrated that Int407 cells expressed the lectin-like oxidized-LDL receptor (LOX-1), the upregulation of which by oxidized-LDL potentiates the transcytosis of BSDL, whereas carrageenan and to a lesser extent polyinosinic acid and fucoidan decrease the enzyme transcytosis. The mAb JTX92, which blocks the LOX-1 receptor function, also impaired the BSDL transcytosis. To confirm these results, the cDNA encoding the human intestinal receptor LOX-1 has been cloned, inserted into vectors, and transfected into Int407 cells. Overexpression of LOX-1 by these cells leads to a substantial increase in the BSDL transcytosis. Globally, these data support the view that LOX-1 could be an intestinal receptor for BSDL, which is implicated in the transcytosis of this enzyme throughout Int407 cells.

INTRODUCTION

The bile salt–dependent lipase (BSDL, EC 3.1.1.13), also referred to as carboxyl ester lipase or bile salt–stimulated lipase, is a lipolytic enzyme, synthesized and secreted by the exocrine pancreas (Lombardo, 2001). The secretion of this digestive enzyme requires the participation of the Grp94 molecular chaperone (Bruneau and Lombardo, 1995; Bruneau et al., 1998). Once in the lumen of the duodenum, BSDL, in concert with other pancreatic lipolytic enzymes and preduodenal lipase, acts to complete the digestion of dietary lipids. Indeed, upon activation by primary bile salts, BSDL catalyzes the duodenal hydrolysis of cholesterol esters into free cholesterol and fatty acids before their absorption by intestinal cells (Howles et al., 1996; Lombardo et al., 1980; Lombardo and Guy, 1980; Weng et al., 1999). Although controversial (Howles et al., 1996), BSDL could also participate in the intestinal free cholesterol absorption (Lopez-Candales et al., 1993), acting as a cholesterol transfer protein (Myers-Payne et al., 1995), or as a cholesterol reesterifying enzyme after cholesterol absorption by intestinal cells (Bhat and Brockman, 1982).

A fraction of BSDL, possibly associated with Grp94, reaches the vicinity of microvilli and upon binding to the surface of intestinal cells is internalized and transported up to the blood compartment (Bruneau et al., 1998, 2000a, 2000b, 2003). Consequently, BSDL has been reported in the plasma of normolipidemic patients (Lombardo et al., 1993) where it associates with apolipoprotein B-containing lipoproteins such as low-density lipoprotein (LDL), chylomicron and very-low-density lipoprotein (VLDL; Bruneau et al., 2003).

The pathway of BSDL throughout intestinal cells has been recently delineated using Int407 cells (Bruneau et al., 2001), which do not express BSDL. When added to the apical reservoir of Transwell-grown Int407 cells, BSDL was shown to first interact with the apical membrane. Further, BSDL forms clusters that are internalized via clathrin-coated pits. After endocytosis, BSDL is directed to a multivesicular compartment, and then the protein transited through the Golgi apparatus where it colocalized with the KDEL retrieval-receptor. Finally, enzymatically active intact BSDL that had experienced this transcytotic motion was released at the basolateral membrane level. The transit of BSDL throughout

© 2003 by The American Society for Cell Biology
the Golgi compartment is compatible with the involvement of the enzyme in the assembly and secretion of chylomicrons (Kirby et al., 2002) and the association of BSDL with these lipoproteins after intestinal transcytosis (Bruneau et al., 2003).

Although a receptor for BSDL on intestinal cell membranes has not been identified, the initial interaction of the protein with CaCo-2 human intestinal cells is mediated by its binding to putative low-affinity and high-capacity binding sites (Huang and Hui, 1990). Structural elements of BSDL potentially implicated in its interaction with a receptor present at the apical membrane of enterocytes are multiple. These are as follows: 1) the heparin-binding site present on BSDL, which could recognize heparin-like molecules lining microvilli membranes (Bösner et al., 1988); 2) N-linked glycan structures that can bind to mannose/fucose lectin receptors (Sallusto et al., 1995); and 3) finally, O-linked mucin-type structures of the C-terminal domain of BSDL (Wang et al., 2001, 2003). The goal of this study was to characterize the receptor(s) involved in the transcytosis mechanism of BSDL using the human intestinal Int407 cells as model. Data support the view that the lectin-like oxidized-LDL receptor (LOX-1) is, at least partly, implicated in the transcytosis of BSDL throughout intestinal cells.

MATERIALS AND METHODS

Reagents

Human transferrin, FITC-conjugated goat anti-rabbit IgG antibodies, FITC-labeled antibodies to goat IgG, peroxidase-labeled antibodies to biotin, heparan sulfate from bovine intestine (Isel-D’Abeau-Chenes, France). [35S]Methionine (trans-[35S] label; >1000 Ci/mmol) was from ICN Biochemicals (Costa Mesa, CA). Affinity-purified rabbit polyclonal antibodies against human pancreatic BSDL (pAbL64) were homemade (Abouakil et al., 1988). An mAb (mAbJ28) to the fucosylated J28 epitope of BSDL (Mas et al., 1997) was a gift of Dr. M-J. Escribano (INSERM, Marseilles, France).

Mouse monoclonal antibodies to transferrin receptor (CD71, clone H6.8.4) were from Zymed (San Francisco, CA). Rabbit polyclonal antibodies to LDL receptor and to Grp94 were from Progen (Heidelberg, Germany) and StressGen (Victoria, Canada), respectively. Goat polyclonal antibodies to the N-terminal (N-14) and to the C-terminal (E-19) domain of the lectin-like oxidized-LDL receptor (LOX-1) were from Santa Cruz Biotechnology (Santa Cruz, CA). A functional blocking antibody 1N1-Terminal was provided by Dr. T. Sawamura (Osaka, Japan). Human native LDLs were isolated from pooled fresh sera by sequential ultracentrifugation, dialyzed, sterilized by filtration, and stored under nitrogen (Augé et al., 1999).

LDLs were acetylated (Ac-LDL) according to standard procedures (Goldstein et al., 1980). Mildly oxidized (Ox)-LDLs were prepared by UV-C irradiation (Augé et al., 1999). Human BSDL was isolated from human pancreatic juice (Lombardo et al., 1995). Before use, the gel was alternatively washed with basic (0.1 M sodium phosphate, pH 8.0) and acidic (0.1 M Mes, pH 5.5) buffers.

Cell Culture and Metabolic Labeling

Human intestinal Int407 cells (ECACC Nbh85051004) were cultured in Eagle's minimum essential medium (EMEM, Invitrogen, Cergy Pontoise, France), supplemented with 2 mM glutamine, 10% (vol/vol) fetal calf serum (FCS), 1% (vol/vol) essential amino acids. For each experiment, cells were plated at a density of 2 × 10^4 cells per well on 12-mm polycarbonate permeable supports (Transwell filter inserts, 0.4-µm pore sizes, Corning Costar, Issy-les-Moulineaux, France) for 5 d, to obtain a tight monolayer (Bruneau et al., 2001). Metabolic labeling of proteins was performed on cell grown in methionine-free DMEM for 45 min. Once starved, cells were pulse-labeled with [35S]methylionine (20 µCi/ml) for 6 h and then washed with complete FBS.

Chemical Cross-linking

Int407 cells grown on Transwell inserts were washed with the FCS-free MEEM and incubated with BSDL (100 nM) for 15 min at 4°C. Cells were then washed with complete PBS and subjected to chemical cross-linking (30 min, 4°C) by the addition of 1 mM diithiobisuccinimidyl propionate (DSP) in PBS. The cross-linking reaction was terminated by addition of 10 mM glycine (10 min, 4°C), and cells were washed twice with cold PBS. Cells were then prepared either for immunofluorescence microscopy or for Western blotting. For immunofluorescence microscopy, after washing cells were fixed and incubated with PBS, bovine serum albumin 1% (PBS-BSA) for 30 min and further incubated for 120 min at room temperature with pAbL64 in PBS-BSA. Cells were washed and incubated with FITC-anti-IgG antibodies (diluted 1/100 in PBS-BSA). Finally, cells were washed with PBS, and filters were mounted on glass slides in the Dabco 10%, glycerol 50%, PBS. Cells were photographed using a fluorescence microscope (BHR2-RFCA Olympus, Hamburg, Germany). For Western blotting, cells were harvested and lysed in lysis buffer (10 mM HEPES, pH 7.4, buffer, 200 mM NaCl, 2 mM EDTA, and 1.5% Triton X-100, 10 µg/ml leupeptin, 2 mM benzamidine, PMSF, Soya-bean trypsin inhibitor and β-phenyl propionate [2 mM each]). Cell lysate was centrifuged. Cell lysate was centrifuged, and BSDL complexes were detected by Western blotting using pAbL64 antibodies.

Biotinylation of Apical Cell Surface Proteins

Monolayers of Int407 cells cultured on Transwell inserts, were washed with PBS and incubated for 1 h at 4°C with 1 mg/ml N-hydroxysuccinimide-long chain-biotin (NHS-LC-biotin, Pierce, Rockford, IL) in sodium bicarbonate, pH 8.0 buffer added in the apical reservoir. At the end of the incubation, the biotinylation agent was removed and the reaction stopped with 0.1 M glycine (10 min, 4°C). Cells were washed with PBS and lysed in the Sepharose-immobilized-BSDL column loading buffer (5 mM Mes pH 6.0 buffer, 0.5% Nonidet P-40, 0.1 M NaCl and protease inhibitors) by sonication (15 s, 4 W). The lysate was centrifuged (20 min, 5000 × g, 4°C). The lysate was electrophoresed, and BSDL complexes were detected by Western blotting using pAbL64 antibodies.

Effects of Various Ligands on the Transepithelial Movement of BSD

Int407 cells were cultured on Transwell inserts, washed twice with FCS-free EMEM, and preincubated with ligands, lectins, or antibodies in FCS-free medium for 1 h in an apical reservoir. Cells were incubated for another 3 h with ligands, lectins, or antibodies in the presence of pancreatic BSDL (100 nM) in the apical reservoir, whereas fresh FCS-free EMEM medium was added in the basolat-
eral reservoir. Alternatively, a preincubation of BSDL (100 nM) with ligands, lectins, or antibodies, followed by the incubation of the putative complexes thus formed, with cells in the apical reservoir was performed. At the end of the incubation apical and basolateral media were collected and used for determination of BSDL (activity and Western blotting).

**PAGE and Western Blotting**

Gel electrophoreses (SDS-PAGE) were performed according to Laemmli (1970). After SDS-PAGE, proteins were electrophoretically transferred onto a nitrocellulose membrane (Burnette, 1981). Western blottings were performed using pAbL64 antibodies to BSDL. The antigen-antibody complexes were detected using chemilluminiscence (Roche, Mannheim, Germany). Quantitations of protein were performed by scanning fluororadiogram using NIH Image program.

**Enzyme Assays**

The BSDL activity was determined on 4-nitrophenyl hexanoate (Gjellesvik et al., 1992).

**One-cycle Immunoprecipitation and Recapture of LOX-1 by BSDL**

Radiolabeled 35S-labeled proteins eluted from the Sepharose-immobilized BSDL column were used for immunoprecipitation. For one-cycle immunoprecipitation the eluted material was incubated overnight (4°C) in presence 20 μg of antibodies to LOX-1 receptor (antibodies N-14 and E-19, 1/1 by vol mix). Prewashed protein A+ and protein G-Sepharose (5 mg each) were added to antibody-antigen complexes and incubated under agitation (4 h, 4°C). The antigen-antibody protein-A/G complexes were then recovered by centrifugation (10,000 × g, 20 min). The pellet was washed twice with the washing buffer supplemented with 1 M NaCl, with the last buffer supplemented with 0.1% SDS and with 10 mM Tris/HCl buffer, pH 7.4, containing 5 mM EDTA. Recapture of immunoprecipitated material was performed using E-19 and N-14 antibodies to LOX-1 receptor coupled with the gel of the Seize primary immunoprecipitation kit (Pierce, Brebières, France). For this purpose radiolabeled cell proteins were subjected to immunoprecipitation with E-19 or N-14–coupled gel. After elution the immunoprecipitated material was recaptured by incubation with BSDL (100 nM) or without BSDL (control) for 4 h, and additional pAbL64 antibodies to BSDL were added and incubated overnight (4°C). Protein A-Sepharose (10 mg) prewashed with the binding buffer was incubated with receptor-ligand antibody complexes for another 4 h. At the end of incubation, these complexes were recovered by centrifugation (10,000 × g, 15 min, 4°C). The pellet was then washed twice with the washing buffer (10 mM Tris/HCl, pH 7.4, 25 mM EDTA, and 1% Triton X-100), with the washing buffer supplemented with 1 M NaCl, and twice again with 10 mM Tris/HCl, pH 7.4, 5 mM EDTA.

Pellets obtained in both experiments were transferred into the Laemmli’s sample buffer (Laemmli, 1970), boiled for 2 min, centrifuged, and electrophoresed on SDS-PAGE. Gels were stained with Coomassie blue R250, destained in ethanol/acetate acid water (2/3/35 by volume), and autoradiographed using BioMax MS FILM (Eastman Kodak, Rochester, NY).

**Reverse Transcription and PCR**

Total mRNA was isolated with Trizol (Invitrogen) from Int-407 cells. RNA (1 μg) was reverse-transcribed (RT) with oligo-dT primers using the M-MLV reverse transcriptase (Promega, Madison, WI) following manufacturer instructions. RT material (5 μl) was amplified by PCR with Taq DNA polymerase (Ozyme, St. Quentin/Yvelines, France) using forward primer, (5'-TCTATCATTCT-TAgCTTTgAAATTggAAATg-3') and reverse primer, (5'-TCACTg-TgCTCTTAgTTTgCCTT-3') specific to LOX-1 (Genset, Evry, France). For PCR, 30 cycles were used at 94°C for 40 s, 55°C for 1 min, and 72°C for 1 min. The RT-PCR fragment (~0.9 kb) was then cloned in the pCR-II TOPO plasmid (Invitrogen) and sequenced. The sequence of this transcript matched totally that of the CDNA encoding human LOX-1 receptor (Adachi et al., 1997). This CDNA was subcloned into pBK vector (Stratagene, Amsterdam, The Netherlands) and named pBK-LOX-1 and alternatively into pEGFP-N1 (Clontech, Saint Quentin Yvelines, France), without fusion of LOX-1 with the EGFP, to give pLOX-1.

**Expression of LOX-1 Receptor**

Stable transfection of Int407 cells was performed using a lipopolyamine-mediated transfection procedure according to the manufacturer (Lipofectamine, Invitrogen). The selection of stable clones was performed for 3 weeks in selection EMEM-medium with G418 (500 μg/ml medium). The surviving cells were trypsinized and cloned by end-limiting dilution method. Stably transfected clones were maintained under the same selection conditions. Two positive clones, one referred to as Int-407 clone 14 (cells transfected with pLOX-1) and another referred to as Int-407 clone 2 (cells transfected with pBK-LOX-1) were selected for further experiments.

**Flow Cytometry**

Detection of LOX-1 at the surface of Int407 cells was carried out by indirect fluorescence. Cells were released from culture plates by treatment with nonenzymic cell dissociation solution (Sigma) for 15 min at 37°C. All subsequent steps were carried out at 4°C. The cells were washed three times in PBS, fixed with 2% paraformaldehyde in PBS for 10 min, and washed extensively with PBS-BSA. Int407 cells were incubated with E-19 antibodies to the extracellular domain of the LOX-1 receptor for 1 h, washed three times with PBS, and finally incubated for 30 min with FITC-labeled secondary antibodies. The cells were then washed, resuspended in Isolow buffer, and analyzed on an EPICS Profile II flow cytometer (Coulter, Hialeah, FL).

**RESULTS**

**Interaction of Pancreatic BSDL with Int407 Cell Membrane Proteins**

In a recent study, we have shown that BSDL is transported from the apical to basolateral pole of Int407 cells. This pancreatic protein seems to be specifically internalized by receptor-mediated endocytosis via clathrin-coated pits and seems to be excluded from other endocytic pathways such as those involving caveolae (Bruneau et al., 2001). The intestinal human cell line Int407 constitute a potent epithelial intestinal cell model to characterize a putative receptor involved in the transcytosis of BSDL.

We have first attempted to demonstrate the association of BSDL with proteins present at the apical membrane of Int407 cells. For this purpose, cell monolayers were grown on a Transwell insert to obtain a tight epithelium and incubated with human BSDL for 15 min at 4°C. At the end of the incubation period, cells were exhaustively washed with complete PBS and subjected to chemical cross-linking with DSP. In control experiments, DSP was omitted. Once the cross-linking reaction was terminated, cells were washed with complete PBS and incubated with pAbL64 antibodies, followed by FITC-labeled anti-IgG and examined for immunofluorescence. As shown in Figure 1A, no fluorescence can
be detected on control cell membranes, whereas a strong reactivity was obtained with cells that have experienced the chemical cross-linking. Thus BSDL can be coupled to proteins present at the membrane of Int407 cells. These cells were then harvested and lysed, and proteins were resolved by SDS-PAGE. After transfer onto nitrocellulose membranes, blots were probed with pAbL64 as primary antibodies and FITC anti-rabbit IgG as second antibodies. (B) Int407 cells incubated as in A were lysed, and the cleared homogenate was then analyzed on SDS-PAGE and Western blotting using pAbL64 and chemiluminescence Western blotting kit.

**BSDL Transcytosis and Ligand Competition**

We furthered this study by determining ligand specificity of the intestinal receptor of BSDL. The enzyme has been shown to associate with the molecular chaperone Grp94 (Bruneau et al., 1998, 2000b) and with transferrin (Erlanson-Albertsson et al., 1985) in pancreatic and duodenal fluids. Therefore, BSDL may be taken up by receptors that internalize Grp94 or transferrin. To determine whether these companion proteins are involved in the BSDL uptake by and transcytosis throughout Int407 cells, we incubated the human enzyme with either Grp94 (10 μg/ml) or transferrin (10 μg/ml) in FCS-free medium for 30 min at 37°C to restore in vitro eventual complexes. Then the mixtures were added in the apical reservoir and incubated for 3 h; thereafter the amount of BSDL that had transcytosed up to the bottom reservoir was determined by recording the enzyme activity. Any of the ligands used had an effect on the BSDL activity. As illustrated in Figure 3 and in the conditions used, neither Grp94 nor transferrin affected the amount of transcytosed BSDL. Also, a 30-min preincubation of Int407 cells with 10 μg/ml antibodies specific to Grp94 or to transferrin receptor (which is expressed by Int407 cells; unpublished data) had no significant effect on BSDL transcytosis. Only specific polyclonal pAbL64 and monoclonal mAbJ28 antibodies to BSDL significantly decrease the transcytosis of the enzyme throughout Int407 cells.
These data indicated that under our experimental conditions, the transcytosis of BSDL may neither implicate the Grp94 protein and the Grp94-receptor (Wassenberg et al., 1999) nor be mediated via the transferrin receptor (Dautry-Varsat et al., 1983; Marsh et al., 1995). Therefore, only antibodies to BSDL impaired the transcytosis of the protein possibly by binding to structural elements involved in the interaction of the protein with its intestinal receptor. These structural elements can be the N- and O-linked glycans of BSDL, which bore epitopes recognized by pAbL64 and mAbJ28 and that carry out oligomannosidic and fucosylated structures (Sugo et al., 1993; Mas et al., 1993; Wang et al., 1995, 1997). The heparin-like binding site of the enzyme (Wang and Hartsuck, 1993) could also be implicated. We thus investigated whether these structural elements are involved and further attempted to characterize ligand specificity of the BSDL putative intestinal receptor.

These structural elements can be the N- and O-linked glycans of BSDL, which bore epitopes recognized by pAbL64 and mAbJ28 and that carry out oligomannosidic and fucosylated structures (Sugo et al., 1993; Mas et al., 1993; Wang et al., 1995, 1997). The heparin-like binding site of the enzyme (Wang and Hartsuck, 1993) could also be implicated. We thus investigated whether these structural elements are involved and further attempted to characterize ligand specificity of the BSDL putative intestinal receptor. For this purpose the effects of various ligands, which have been shown to hinder glycoprotein interaction with specific receptors or to inhibit oxidized-LDL binding to class A and B scavenger receptors and to the lectin-like Ox-LDL receptor (LOX-1; Moriwaki et al., 1998; Shirai et al., 1999), were examined. First of all, to rule out the possibility that BSDL interacted with the cell via the mannose/fucose lectin receptor (Avraméas et al., 1996), we performed competition experiments using mannan as a competitor (Arnold-Schild et al., 1999). No inhibitory effect was observed using this ligand at a concentration of 1 mg/ml (Figure 4A), whereas 0.3 mg/ml mannan was shown to inhibit completely the uptake of FITC-dextran by the mannose/fucose lectin receptor of dendritic cells (Sallusto et al., 1995). Heparin (0.1 and 1 mg/ml) partially decreased the amount of BSDL present in the bottom reservoir, whereas neither heparan sulfate (1 mg/ml) nor chondroitin sulfate (200 μg/ml) had important effect on BSDL transcytosis (Figure 4A). Other carbohydrate compounds used at lower concentration (100 μg/ml) such as kappa-carrageenan (a polysaccharide extracted from the lichen Eucheuma cottonii and composed predominantly of sulfated galactose residues) quite totally annihilates the transcytosis of BSDL. Fucoidan (a polysaccharide extracted from the brown algae Fucus vesiculosus and composed predominantly of sulfated galactose residues) at comparable concentration is a little less efficient than carrageenan in inhibiting the enzyme transcytosis. Polyanionic nucleic acid such as poly-cytidylate had also no effect, albeit the four-stranded polyinosinic acid had an inhibitory effect at either 100 or 200 μg/ml. This study was completed by determining the effects of various lectins on BSDL transcytosis. For this purpose
monolayers of Int407 cells were preincubated with lectin (20 μg/ml in the culture medium) applied for 1 h in the apical reservoir. The culture medium was then removed, and BSDL (100 nM) was added with lectin in the apical reservoir. After 3-h incubation the amount of transcytosed BSDL was determined in the basolateral reservoir. As shown on Figure 4B, only concanavalin A (ConA), which primarily recognizes oligomannosidic structures, decreased by some 70% the transcytosis of BSDL, whereas peanut agglutinin (PNA) and Ulex europeaus I lectin (UEA-I) had a poor effect. These two lectins bound to O-linked glycans and to fucose residues α (1–2) linked to galactose, respectively.

These data suggest that the uptake of BSDL that precedes its transcytosis throughout Int407 cells did not involve the mannose/fucose lectin receptor, which is implicated in the macropinocytosis of glycosylated macromolecules (Arnold-Schild et al., 1999). Nevertheless, it seems evident that carbohydrate structures of BSDL are implicated in the interaction of the enzyme with its receptor. Furthermore, the inhibition of BSDL transcytosis promoted by reagents used above also suggest that class A or B scavenger receptors or LOX-1 could be, at least partly, implicated in the BSDL uptake by Int407 cells. Many facts indicate that these receptors could be actually involved in BSDL interaction with intestinal cell membranes. First, scavenger receptors, in general, have been shown to bind polysaccharides (Hampton et al., 1991). Second, class B scavenger receptors were located in intestine (Cai et al., 2001) where they catalyze cholesterol uptake (Hauser et al., 1998). Third, BSDL, which is involved in cholesterol absorption (Lombardo, 2001), is also susceptible to associate with lipoprotein structures such as LDL (Cailol et al., 1997), receptors of which are also expressed by intestinal cells (Fong et al., 1995).

All these results suggest that the putative intestinal receptor of BSDL is a 50-kDa protein that recognizes glycan structures. This receptor could be a lectin-like receptor. The 50-kDa receptor LOX-1 has been characterized as such lectin-like receptor (Metha and Li, 2002); therefore we focused on this receptor. First, we determined whether the intestinal cell line Int407 synthesized LOX-1 and expressed the receptor at their cell surface. The cell surface expression of this receptor was analyzed by flow cytometry using E-19 antibodies to the extracellular domain of LOX-1 receptor. As shown in Figure 5A, compared with control in which these primary antibodies were omitted, a net increase in fluorescence was observed when Int407 cells were treated with E-19 antibodies. This result strongly suggests that LOX-1 receptor is expressed at the apical surface of Int407 grown to form a tight epithelium. Second, the radioactive material eluted with the buffer B in Figure 2 has been further immunoprecipitated with a vol/vol mixture of E-19 and N-14 antibodies to LOX-1. The material thus immunoprecipitated was resolved on SDS-PAGE and autoradiographed. As shown in Figure 6A, a main band representing a protein of ~50 kDa can be detected, suggesting that this protein interacting with the Sepharose-immobilized BSDL is actually LOX-1. Finally, recapture experiment was performed (Figure 6B). When radiolabeled cell proteins were immunoprecipitated with antibodies to LOX-1 (E-19 and N-14 coupled to Seize gel), eluted, and analyzed on SDS-PAGE, three main bands were detected (Figure 6B, lane 1). The material eluted, using pH 2.8 glycine buffer and neutralized with Tris/HCl buffer (pH
9.5) to avoid denaturation as specified in the protocol of the immunoprecipitation kit, was further recaptured by incubation with BSDL and material susceptible to bind BSDL was then immunoprecipitated with pAbL64. Results of this recapture cycle showed that only one protein of ~50 kDa can be specifically isolated (Figure 6B, lane 2, arrowhead). These data indicated that the 50-kDa protein immunoprecipitated with antibodies to LOX-1 recognized BSDL. Control omitting BSDL in recapture experiment did not allow isolating the 50-kDa protein (Figure 6B, lane 3).

To define the involvement of LOX-1 in the BSDL transcytosis, monolayers of Int407 cells were incubated for 1 h with polyclonal antibodies (N-14 or E-19) directed against LOX-1 or with mAb JTX92 (described as a blocking antibody for the LOX-1 receptor function) or with antibodies to the LDL-receptor applied in the apical reservoir. Cells were then washed and BSDL added in fresh medium containing each antibodies. After 3-h incubation under standard conditions, the amount of transcytosed BSDL was determined by recording the enzyme activity in the basolateral reservoir. As shown on Figure 3, although antibodies to the LDL receptor or to LOX-1 (N-14 or E-19) were ineffective in inhibiting the transcytosis of the enzyme, mAb JTX92 decreased the transport of BSDL throughout Int407 cells.

These data demonstrated that the LOX-1 receptor is actually expressed at the apical surface of Int407 cells and that LOX-1 may interact with BSDL and could be involved in the transcytosis of BSDL.

**LOX-1 Implication in BSDL Transcytosis**

Because the expression of LOX-1 may be upregulated by Ox-LDL and by atherogenic components of oxidized lipoproteins (Aoyama et al., 1999, 2000), we examined the effects of incubation of Int407 cells with native and modified LDL (40 μg/ml), on the amount of transcytosed BSDL. For this purpose, Int407 cells were incubated for 24 h with LDL

---

**Figure 4.** Effect of various ligands on BSDL transcytosis. (A) Int407 cells were cultured as described in the legend of Figure 3. Cell culture medium of the apical reservoir was removed at time 0 and replaced by media containing BSDL (100 nM) and ligands at the final concentration as indicated. (B) Int407 cells were separately preincubated for 1 h with each lectin (20 μg/ml), and after removal of the culture medium, Int407 cells were further incubated for 3 h with fresh medium containing BSDL (100 nM), and lectin was applied in the apical reservoir. (Con A, concanavalin A; PNA, peanut agglutinin; UEA-1 = Ulex Europeaus-1 lectin). After 3-h incubation, medium of the bottom reservoir of each insert was removed, and the amount of transcytosed BSDL was evaluated from its activity. Values are expressed as percentage of control performed in the absence of ligand (control) and are means ± SD of at least three independent experiments.
Bidirectional Transport of BSDL

We next wondered whether the transport of BSDL may be bidirectional. For this purpose BSDL (100 nM) was applied (native or modified), and then the apical reservoir medium containing LDL was withdrawn, and fresh medium containing BSDL (100 nM) was added and incubated for another 3 h before recording BSDL in the bottom reservoir. As illustrated in Figure 7, Ox-LDL does increase the amount of BSDL detected in the bottom reservoir, whereas neither native LDL nor Ac-LDL promote such effect. This result suggested that Ox-LDL increases the rate of the BSDL transcytosis possibly by an enhancement of the expression of the LOX-1 receptor.

We next examined the effect of Ox-LDL on the expression of lox-1 RNA transcripts in Int-407 cells. For this goal, intestinal cells were grown for 24 h in the absence or in the presence of Ox-LDL (40 μg/ml); at the end of the incubation period, cells were washed and harvested, and RNA was extracted. RNA was then used as matrix for RT-PCR using a pair of oligonucleotide primers specific for human LOX-1. Products were further analyzed on agarose gel (Figure 8). Under conditions used and even though at least three attempts were done, it was quite difficult to detect RT-PCR product from RNA of Int407 cells grown in absence of Ox-LDL, whereas a 0.9-kb transcript was clearly obtained after the RT-PCR using RNA extracted from cells incubated with Ox-LDL. This transcript showed an open reading frame of 933 base pairs, the sequence of which (unpublished data) matched totally that of human LOX-1 (Adachi et al., 1997; Sawamura et al., 1997). This cDNA was then subcloned into two eukaryotic expression vectors, pEGFP-N1 and pBK-CMV under the control of SV40 and CMV promoter to give pLOX-1 and pBK-LOX-1 vectors, respectively. Int407 cells were transfected with these expression vectors and then selected by end-dilution, and two cell clones, one referred to as Int-407 clone 14 (cells transfected with pLOX-1) and another referred to as Int-407 clone 2 (cells transfected with pBK-LOX-1), were also used. These two clones expressed different amount of LOX-1 transcripts as assessed by RT-PCR (Figure 9A). Flow cytometry experiments demonstrated (see Figure 5B) that the cell surface expression of LOX-1 is higher in transfected Int407 cells than in the wild-type cell. Furthermore, clone 2 fluorescence is a little higher than that of clone 14, suggesting that the amount of LOX-1 receptor expressed at the surface is higher in clone 2 than in clone 14. Therefore, these two selected clones were grown on Transwell inserts until a tight epithelium was reached and assayed for BSDL transcytosis under standard conditions. As shown in Figure 9B, compared with wild Int407 control cells, transfected cells allow a significant increase in BSDL transcytosis, by 300 and 500% by Int407 clone 14 and clone 2, respectively. Therefore, amount of BSDL that had transcytosed is directly proportional to the amount of RT-PCR transcripts (compare Figure 9, A and B) and to the amount of LOX-1 receptors expressed at the cell surface (see Figure 5B). These data confirmed that LOX-1 receptor participates in the BSDL transcytosis. We further examined the BSDL transcytosis under conditions in which the apical reservoir was buffered between pH 4 and pH 8. No modification in BSDL transcytosis occurs under these conditions (our unpublished results).

Bidirectional Transport of BSDL

We next wondered whether the transport of BSDL may be bidirectional. For this purpose BSDL (100 nM) was applied.
trifugation (20 min, 10,000 g, 4°C). The material eluted with buffer B was immunoprecipitated with antibodies (N-14 and E-19, 1-to-1 mix) to LOX-1 receptor and resolved on SDS-PAGE, followed by autoradiography. (B) Radiolabeled proteins of Int407 cells were subjected to the two-cycle immunoprecipitation procedure using E-19 and N-14 antibodies to LOX-1 coupled to the Seize gel. The radio-labeled material bound to antibodies was eluted and either separated on SDS-PAGE and autoradiographed (lane 1) or recaptured by incubation with BSDL (100 nM, 4 h), and the material interacting with the enzyme was immunoprecipitated with antibodies to BSDL (pAbL64) and analyzed on SDS-PAGE as above (lane 2). Control experiment was performed by omitting BSDL in the recapture experiment (lane 3).

to apical or basolateral surface of Int407 cells. As assessed by Western blotting and activity, after 3 h at 37°C intact BSDL applied to apical or basolateral cell surfaces was transported in both luminal and abluminal directions across Int407 cell monolayers. However, when monolayers were incubated at 4°C, the transport of BSDL was largely reduced (Figure 10). The same relative decrease in BSDL transcytosis rate at 4 vs. 37°C was also observed with LOX-1–transfected Int407 cells (unpublished data). Thus, transepithelial flux of BSDL did not occur by passive diffusion through intercellular tight junctions or monolayer leaks. These data indicate that BSDL can enter both apically and basolaterally directed transcytosis pathway in Int407 cells. Measurements of band intensities and of activities suggest that the apically directed transport pathway was as efficient as the basolaterally directed transport. Finally, we sought to determine whether the transport of BSDL from the basolateral to the apical compartment also depended upon LOX-1. First, at 37°C this abluminal transport was increased in the same proportion as the luminal transport in Int407 cells overexpressing LOX-1 compared with wild-type cells (unpublished data). This motion was also reduced when recorded at 4°C. Second, we furthered this study using LOX-1 inhibitors as described in Figure 4. Data indicated that, as the apical-to-basolateral transport of BSDL, the basolateral-to-apical transport of the enzyme is also inhibited by carrageenan (0.1 mg/mL, 95±1% inhibition), fucoidan (0.1 mg/mL, 82±5% inhibition), and Con A (20 μg/mL, 90.3±15.5% inhibition), whereas heparin still remained a poor inhibitor (1 mg/mL, 38.3±15.6% inhibition). These data strongly support that LOX-1 mediates BSDL transport in both apical-to-basolateral and basolateral-to-apical directions.

**DISCUSSION**

In the early 1960s, Gallo and coworkers detected BSDL in the rat intestinal cells (Gallo and Treadwell, 1963), a result that was confirmed by us in human (LecheÌena de la Porte et al., 1987) and rat (Bruneau et al., 1998). We have further shown that BSDL is present on microvilli, in the endosomal compartment, and in interdigitations of the basolateral membrane of enterocytes (Bruneau et al., 1998). Recently, using Int407 human intestinal cells, we have shown that pancreatic BSDL formed clusters, in association with clathrin-coated pits at the apical surface, which were then internalized. Subsequent to internalization, coated vesicle-containing BSDL fuse with a nocodazole-sensitive multivesicular compartment. The protein then transited through the Golgi apparatus and the intact enzymatically active protein is further released at the basolateral level (Bruneau et al., 2001).

We have further demonstrated that the circulating BSDL originated from the pancreatic secretion via the intestinal transcytosis (Bruneau et al., 2003). Very few macromolecules traverse the epithelial barrier intact by passive diffusion (Harada et al., 1994a, 1994b). However some macromolecules are efficiently transported across epithelial cells. This transcellular pathway of macromolecular transport termed transcytosis is most often receptor-mediated, as exemplified by the mechanism for the mucosal secretion of polymeric IgA by the polymeric immunoglobulin receptor (pIGA-R, Mostov and Blobel, 1983) and IgG by the MHC-class-I-related Fc receptor (FcRn; Dickinson et al., 1999). Macromolecular transcellular transport can occur by fluid-phase or non-receptor-mediated endocytosis, but this pathway is inefficient, and most of endocytosed cargo is delivered to lysosomes for degradation (Futter et al., 1996). Therefore, we can suggest that BSDL interacted with an apical receptor likely located in clathrin-coated pits, before its motion through intestinal cells. Although a receptor for BSDL in intestinal cells has not been identified, binding studies using a heterologous system (i.e., human intestinal CaCo-2 cells and porcine BSDL) have shown that the initial interaction of the enzyme with these cells is mediated by the binding of BSDL to putative low-affinity and high-capacity binding
sites at the cell surface (Huang and Hui, 1990). In the present study, we have attempted to characterize this receptor. It has been hypothesized that the heparin-binding site present on BSDL (Fält et al., 2001) could be involved in such binding (Bosner et al., 1988). As shown here, heparin at concentration up to 1 mg/ml only partially impaired the uptake of BSDL by the cells (as assessed by the amount of enzyme activity recorded in the basal reservoir of Transwell inserts). This suggests that the enzyme could interact, albeit with a poor avidity, with brush-border membrane-associated, heparin-like molecules before internalization. These heparin-like molecules could be part of proteoglycans. However, the lack of heparan sulfate effect indicated that these proteoglycans are not related to the syndecan family, which is composed of transmembrane heparan sulfate proteoglycans (Mali et al., 1990) described as alternative receptors or coreceptors for the uptake of lipoprotein lipase-bridged atherogenic lipoproteins (Williams et al., 1992; Fuki et al., 1997). Other sulfated glycans such as chondroitin sulfate are also poorly efficient in inhibiting the transcytosis of BSDL throughout Int407 cells. Also internalization of the enzyme via the transferrin receptor (present at the cell surface of Int407 cells), which is clathrin dependent (Hansen et al., 1993), may not represent a way for BSDL to associate with clathrin-coated pits of the apical membrane of enterocytes because neither transferrin nor antibodies to transferrin-receptor modulate the BSDL motion through intestinal cells.

Figure 7. Effect of Int407 cells preincubation with native and modified LDL on BSDL transcytosis. Int407 cells were grown on Transwell inserts to obtain a tight epithelium. Cells were then independently incubated for 24 h with native or modified LDL (40 μg/ml) in the cell culture medium. Then cell culture medium of the apical reservoir was removed and replaced by media containing BSDL (100 nM). After another 3-h incubation, medium of the bottom reservoir was removed and the amount of transcytosed BSDL evaluated from Western blotting (B), or from its activity (C). For Western blotting (A, only a typical experiment is shown), proteins present in the bottom reservoir (50 μl of medium were separated on SDS-PAGE and electrotransferred onto nitrocellulose membranes). Membranes were then probed with pAbL64. After visualization, quantitation of protein bands was performed using the NIH Image program. Values are expressed as percent of control performed in the absence of LDL preincubation (control). Values are means ± SD of at least three independent experiments.

Figure 8. RT-PCR using RNA extracted from Int407 cells. Int407 cells were cultured until a tight epithelium was formed, and then the culture medium was replaced with fresh medium without or with Ox-LDL (40 μg/ml) and further incubated for 24 h. At the end of the incubation, RNA was extracted and amplified using sense and antisense primers designed to cover the full-length sequence of LOX-1. Amplification products were then separated on 1% agarose gel. Lane 1, ladder; lane 2, cDNA from mock-treated Int407 cells; lane 3, cDNA from Ox-LDL–treated Int407 cells.
Another possibility was the involvement of the N-linked glycan structure of BSDL (Mas et al., 1993). This structure, which is highly variable (Sugo et al., 1993) may help BSDL to interact with mannose/fucose lectin receptor (Avraméas et al., 1996). The molecular chaperone Grp94, once associated with BSDL (Bruneau et al., 1998) can also be internalized via this receptor and macropinocytosis (Arnold-Schild et al., 1999; Wassenberg et al., 1999). Mannose/fucose lectin receptor seems to be not involved in BSDL transcytosis because mannan, a specific competitor of this receptor (Arnold-Schild et al., 1999), does not impair BSDL transcytosis. However, the competitive effect of Con A, a lectin that recognizes the oligomannosidic core of N-linked glycans, suggests that the N-glycosylation of BSDL could be involved.

Finally, the O-glycosylated C-terminal mucin-like tail of BSDL (Wang and Hartsuck, 1993; Wang et al., 1995; Mas et
loess of effect of PNA allowed us to rule out in first instance this assumption. Antibodies to BSDL (pAbL64 and mAbJ28) impaired transcytosis throughout Int407 cells and steric hindrance may be advocated to explain this effect.

Many receptors could be involved in BSDL uptake and transcytosis throughout Int407 cells (Ramprasad et al., 1995; Adachi et al., 1997; Dhaliwal and Steinbrecher, 1999; Shirai et al., 1999; Cai et al., 2001; Lobos et al., 2001; Werder et al., 2001; Gillette-Taylor et al., 2001). Among them the lectin-like oxidized LDL receptor or LOX-1, a 50-kDa protein detected in nearly all tissues examined (Sawamura et al., 1997) has retained our attention. Although carrageenan and polysaccharic acid abolished Ox-LDL binding to LOX-1, fucoidan, chondroitin sulfate and polycytdylic acid are less effective (Moriwaki et al., 1998). A unique feature of LOX-1 is the presence of a lectin-like domain in a conserved C-terminal domain, which is essential for Ox-LDL binding (Chen et al., 2001b).

As mentioned above, the fact that Con A, which is specific for the N-linked glycans of BSDL, blocked the transcytosis of this latter protein indicated that a lectin-type receptor could be involved in the transcytotic mechanism of BSDL.

However, we cannot rule out the binding of Con A to LOX-1, which is also a N-glycosylated protein. From current results it seems obvious that the BSDL receptor of Int407 cells is partially blocked by mAb to LOX-1, upregulated by Ox-LDL as is LOX-1 (Aoyama et al., 1999; Metha and Li, 2002), the mRNA of which can be easily detected upon stimulation of Int407 cells by Ox-LDL. The implication of LOX-1 in BSDL transcytosis is confirmed by the overexpression of LOX-1 in Int407 cells transfected with the cDNA encoding the human LOX-1. This overexpression leads to a substantial increase in the amount of transcytosed enzyme. Taken as a whole, data demonstrated that the transcytosis of BSDL throughout intestinal cells implicates LOX-1. A striking result is the decrease in BSDL transcytosis upon fucoidan treatment of Int407 cells, because fucoidan does not compete with Ox-LDL for binding to LOX-1 (Moriwaki et al., 1998). No clear explanation can be done to this result; however, it is possible that the interaction of BSDL with LOX-1 involves fucose residues of BSDL, an interaction that should be impaired by nonsulfated fucose residues of fucoidan, whereas the interaction between LOX-1 and the protein moiety of Ox-LDL (Moriwaki et al., 1998) could involve ionict and hydrophilic interactions and not actual LOX-1 lectin-binding properties (Chen et al., 2001a, 2001b; Shi et al., 2001). Clearly, if fucose residues of BSDL are involved in the interaction of the enzyme with the LOX-1 receptor, they should not be α(1–2) linked to galactose residues as UEA-1 lectin did not impair BSDL transcytosis. A way to conciliate the binding of BSDL to heparin-like molecules lining the brush border membrane (see Fäll et al., 2001; Bosner et al., 1988) and the implication of LOX-1 would be that BSDL first bind to heparin-like molecules lining intestinal cells and then are transferred to LOX-1 with which the enzyme associates by mean of glycannic determinants. Once bound to LOX-1, BSDL could form clusters that are taken up via clathrin-coated pits of intestinal cells (Bruneau et al., 2001).

The mechanism of LOX-1-mediated BSDL transport in Int407 cells possibly differs from that defined for the plgA-R (Mostov et al., 1980, 2000; Mostov and Blobel, 1983; Apocada et al., 1994) but instead resembles that of FcRn (Dickinson et al., 1999). As observed for this latter receptor, the bidirec-

Figure 10. Bidirectional transcytosis of BSDL through Int407 cells. BSDL (100 nM) was applied either in the apical reservoir to determine the apical-to-basolateral transcytosis or in the basolateral reservoir to determine the basolateral-to-apical transcytosis. Cells were incubated for 3 h at 37°C or at 4°C as mentioned. Analyses were performed by Western blotting using 50-μl sample collected from apical or basolateral reservoir, further quantitated by densitometry and activity determination (total unit recovered in each compartment i.e., mU/ml corrected for the total volume of culture medium in each reservoir). Western blotting shows a typical experiment and histogram values are means ± SD of at least three independent experiments.
tional transcytosis of BSDL through Int407 cells suggests that LOX-1 may reenter the cell for return to the opposite membrane. Thus unlike pIgA-R, which is committed to only one round of dimeric IgA transport, the same LOX-1 molecule could transport BSDL for multiple rounds in both luminal and abluminal direction. Nevertheless, contrary to FcRn, which first binds its ligand within the acidic endosome after fluid phase uptake (Dickinson et al., 1999), as suggested by cross-linking experiments, LOX-1 should rather bind BSDL at the cell surface as pIgA-R does with IgA (Mostov and Blobel, 1983; Apodaca et al., 1994). As a consequence, IgG transport across epithelial cells by FcRn is dependent on the pH and sensitive to bafilomycin A1, which collapses pH gradient in intracellular vesicles, whereas transport of BSDL across Int407 cells did not depend upon pH (our unpublished results) and is insensitive to bafilomycin A1 (Bruneau et al., 2001). Of course the exact mechanism of BSDL transcytosis and the pathway of LOX-1 receptor through Int407 cells need further studies. Another question concerns the release of BSDL from LOX-1 once the complex reached the basolateral domain of intestinal cell membrane. One possibility is that intestinally neo-synthesized lipoprotein particles such as chylomicrons (Hui and Howles, 2002; Bruneau et al., 2003) may help the enzyme to dissociate from LOX-1. However, the involvement of LOX-1 in the BSDL transcytosis does not exclude that of other receptor(s).

ACKNOWLEDGMENTS

We are indebted to Dr. C. Nicchitta (Duke University, Durham, NC) and to Dr. T Sawamura (Osaka, Japan) for its kind gift of porcine pancreatic Grp94 and functional blocking antibodies to LOX-1 receptor, respectively. Our special thanks also go to Dr. A. Salvayre (INSERM U-466, Toulouse, France) for the preparation and gift of native and modified human LDL and to Dr. M-J. Escribano (INSERM U-260, Marseille, France) for the release of mAb J28 antibody. This work was supported by institutional funding from the Institut National de la Santé et de la Recherche Médicale (Paris, France) and by the Université de la Méditerranée.

REFERENCES


